All In MedTech

Device Trial Radar · NCT03599271

A Clinical Evaluation of the Intersect ENT Sinus Device (ASCEND)

The ASCEND Study: A Clinical Evaluation of the UP Drug-Coated Device in Patients With Chronic Rhinosinusitis

Last checked: Nov 19, 2026Latest source record: May 26, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

75

Actual

Start

Jun 12, 2018

Primary completion

Dec 15, 2019

Study completion Dec 9, 2020

Sponsor

Lead sponsor
Intersect ENTNot on our public-company list
Sponsor type
Industry
First posted
Jul 26, 2018

More device trials from this sponsor

Design

Study type
Interventional
Allocation
Randomized
Model
Sequential
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of the ASCEND Study is to assess the safety, performance, and efficacy of the Intersect ENT UP Drug-Coated Device when used in chronic rhinosinusitis (CRS) patients undergoing balloon dilation of frontal sinus ostia (FSO)

Conditions

  • Chronic Rhinosinusitis (Diagnosis)

Interventions

  • Drug-Coated DeviceDevice

    3000 mcg mometasone furoate-coated sinus dilation device

  • Control DeviceDevice

    Sinus dilation device without drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Randomized Cohort: Difference in Patency Grade of FSOTime frame: 30 days
  2. The Number of Participants in the PK Cohort With Successful Dilation of Attempted FSO at BaselineTime frame: Baseline

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centers for Advanced ENT Care

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.